Asymmetrical effects of deafness-associated mitochondrial DNA 7516delA mutation on the processing of RNAs in the H-strand and L-strand polycistronic transcripts

Yun Xiao1,2,3,†, Meng Wang1,2,†, Qiufen He1,2, Lei Xu3, Qinghai Zhang1,2, Feilong Meng1,2, Zidong Jia1, Fengguo Zhang3, Haibo Wang3,* and Min-Xin Guan1,2,4,5,*

1Division of Medical Genetics and Genomics, The Children's Hospital, Zhejiang University School of Medicine and National Clinical Research Center for Child Health, Hangzhou, Zhejiang 310058, China, 2Institute of Genetics, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, China, 3Department of Otolaryngology–Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, Jinan, Shandong 250022, China, 4Key Lab of Reproductive Genetics, Ministry of Education of PRC, Zhejiang University, Hangzhou, Zhejiang 310058, China and 5Joint Institute of Genetics and Genome Medicine between Zhejiang University and University of Toronto, Hangzhou, Zhejiang 310058, China

ABSTRACT

In this report, we investigated the molecular mechanism underlying a deafness-associated m.7516delA mutation affecting the 5′ end processing sites of mitochondrial tRNAAsp and tRNASe(UCL). A in vitro processing experiment demonstrated that m.7516delA mutation caused the aberrant 5′ end processing of tRNASe(UCL) and tRNAAsp precursors, catalyzed by RNase P. Using cytoplasmic hybrids (cybrids) derived from one hearing-impaired Chinese family bearing the m.7516delA mutation and control, we demonstrated the asymmetrical effects of m.7516delA mutation on the processing of tRNAs in the heavy (H)-strand and light (L)-strand polycistronic transcripts. Specially, the m.7516delA mutation caused the decreased levels of tRNASe(UCL) and downstream five tRNAs, including tRNAHis and downstream five tRNAs, including tRNAVal from the L-strand transcripts and tRNAAsp from the H-strand transcripts. Strikingly, mutant cybrids exhibited the lower level of COX2 mRNA and accumulation of longer and uncleaved precursors of COX2 from the H-strand transcripts. Aberrant RNA metabolisms yielded variable reductions in the mitochondrial proteins, especially marked reductions in the levels of ND4, ND5, CO1, CO2 and CO3. The impairment of mitochondrial translation caused the proteostasis stress and respiratory deficiency, diminished ATP production and membrane potential, increased production of reactive oxygen species and promoted apoptosis. Our findings provide new insights into the pathophysiology of deafness arising from mitochondrial tRNA processing defects.

INTRODUCTION

The mitochondrial RNA processing is essential for the formation of functional tRNAs used for mitochondrial translation (1–3). In humans, mitochondrial DNA (mtDNA) is circular and composed of two strands: heavy (H) strand encodes 2 rRNAs, 14 tRNAs and 12 polypeptides for essential subunits of the oxidative phosphorylation system (OXPHOS), and light (L) strand codes for 8 tRNAs and 1 polypeptide (ND6) (4,5). mtDNA bidirectionally produces the polycistronic H- and L-strand transcripts, catalyzed by the mitochondrial transcription machinery (6–10). As shown in Figure 1, the transcription of H-strand promoter 1 (HSP1) produces the short transcript containing 12S rRNA, 16S rRNA, tRNAPro and tRNAVal, while the transcription initiated from HSP2 generates an almost genome transcript consisting of 12S rRNA, 16S rRNA, 12 mRNAs and 14 tRNAs, including tRNAAsp, tRNAHis, tRNALeu(UUR) and tRNASe(UCL) (6,7,11,12). Furthermore, the transcription of L-strand promoter (LSP) resulted in a near-genomic length primary transcript encoding eight tRNAs, including tRNAGln and tRNASe(UCL), and ND6 (6,7,11,12). Af-
Figure 1. A schematic representation of the transcription map of human mitochondria and location of the m.7516delA mutation in the precursors of tRNA^{Ser(UCN)} and tRNA^{Asp}.

(A) Three polycistronic RNA transcripts. The transcription of LSP resulted in a near-genomic length primary transcript encoding eight tRNAs and ND6. The transcription of HSP1 generated the short transcript containing tRNA^{Phe}, tRNA^{Val}, 12S rRNA, 16S rRNA, while the transcription from HSP2 produced an almost genome length transcript consisting of 12S rRNA, 16S rRNA, 12 mRNAs and 14 tRNAs. (B) Location of the m.7516delA mutation in the precursors of tRNA^{Ser(UCN)} and tRNA^{Asp}. Cloverleaf structures of tRNA^{Ser(UCN)} and tRNA^{Asp} were derived from (28). Potential 5' end processing sites in the tRNA^{Ser(UCN)} and tRNA^{Asp} precursors catalyzed by RNase P are indicated.

...ter transcription, these polycistronic transcripts are processed to release 13 mRNAs, 22 tRNAs, and 2 rRNAs essential for mitochondrial translation (6,7). The processing of mitochondrial tRNAs from the primary transcripts required the precise cleavage of tRNAs at their 5’ ends, catalyzed by RNase P, and 3’ terminal mediated by RNase Z (13–16). In particular, the mRNA and rRNA at H-strand transcripts are flanked by one or more tRNAs, and the excision of tRNAs releases all other elements and is a prerequisite for RNA maturation. This processing mechanism was referred to as the tRNA punctuation model (7). However, the processing mechanisms of L-strand transcripts are different from those of H-strand transcripts, indicating the existence of complex posttranscriptional regulatory mechanisms (10,17). The aberrant 5’ or 3’ end processing of mitochondrial tRNA precursors has been linked to an array of different diseases, including deafness, cardiomyopathy and hypertension (18–26). The deafness-associated m.7445T>C mutation in the precursor of tRNA^{Ser(UCN)} and cardiomyopathy-associated tRNA^{Leu(UUR)} 4259A>G mutations, and tRNA^{His} 12192G>A mutation perturbed the 3’ end processing of corresponding tRNA precursors (19–21). The tRNA^{Ile} 4263A>G and tRNA^{Ala} 5655A>G mutations at the 5’ end (conventional position 1) of corresponding tRNAs altered the 3’ end processing of tRNA^{Ile} and tRNA^{Ala} precursors, respectively (24,25). Strikingly, the m.4401A>G mutation at the junction of tRNA^{Met} and tRNA^{Gln} genes caused the 5’ end aberrant processing of tRNA^{Met} in the H-strand transcripts and tRNA^{Gln} as well as other seven tRNAs and ND6 mRNA in the L-strand transcripts (26). These suggested the asymmetrical processing mechanisms of H-strand and L-strand polycistronic transcripts (26). However, the pathogenic mechanisms underlying these tRNA processing defects remain elusive.

Most recently, we identified the m.7516delA mutation in one Han Chinese family with maternal inheritance of deafness in a large cohort of Chinese hearing-impaired probands (27). As shown in Figure 1, the nucleotide at position 7516 resided at 3 bp (AAA/TTT) spacers to 5’ ends...
MATERIALS AND METHODS

Subjects and audiological examinations

A hearing-impaired Han Chinese family was recruited from the Shandong Provincial ENT Hospital, Shandong University, as described previously (Supplementary Figure S1) (27). Comprehensive history-taking, physical examination and audiological examination were performed to identify any syndromic findings, history of exposure to aminoglycosides and genetic factors related to hearing impairment in all available members of this Chinese pedigree, as detailed previously (33,34). Informed consent, blood samples and clinical evaluations were obtained from all participating family members under protocols approved by the Ethics Committees of Zhejiang University and Shandong University.

Analysis of mitochondrial DNAs

Genomic DNA was isolated from whole blood of participants using QIAamp DNA Blood Mini Kit (Qiagen, No. 51104). The subjects’ DNA fragments spanning the mitochondrial tRNA^A sp and tRNA^Ser(UCN) genes were PCR amplified by use of oligodeoxynucleotides corresponding to mtDNA at positions 7129–7148 and 8095–8114 (4). Fragment was purified and then analyzed by direct sequencing. The sequence results were compared with the updated consensus Cambridge sequence (GenBank accession number: NC_012920) (35). The entire mtDNAs of the proband III-3 and one Chinese control subject (C17) belonging to the same mtDNA haplotype were PCR amplified in 24 overlapping fragments using sets of the L- and H-strand oligonucleotide primers, as described previously (36). These sequence results were compared with the updated consensus Cambridge sequence, as described earlier.

Cell lines and culture conditions

Lymphoblastoid cell lines were immortalized by transformation with the Epstein–Barr virus, as described elsewhere (37). Cell lines derived from one affected matrilineal relative (III-3) of the Chinese family carrying the m.7516delA mutation and one genetically unrelated control individual (C17) lacking the mutation (Supplementary Table S1) were grown in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS). The bromodeoxyuridine (BrdU)-resistant 143B.TK− cell line was grown in Dulbecco’s modified Eagle medium (Life Technologies) containing 4.5 mg of glucose and 0.11 mg of pyruvate/ml, supplemented with 100 μg of BrdU/ml and 5% FBS. The mtDNA-less ρ0−206 cell line, derived from 143B.TK− cells, was grown under the same conditions as the parental line, except for the addition of 50 μg of uridine/ml. All cybrid cell lines constructed with enucleated lymphoblastoid cell lines were maintained in the same medium as the 143B.TK− cell line. The generation of cybrid cell lines from III-3 and C17 by cytoplasts of mtDNA-less ρ0−206 cells was performed as detailed elsewhere (29–31). The presence and level of m.7516delA mutation and mtDNA copy numbers in cybrid cell lines were analyzed as detailed elsewhere (38). Three mutant cybrids (III-3.1, III-3.2 and III-3.3) carrying the homoplasmic m.7516delA mutation and three control cybrids (C17.1, C17.2 and C17.3) lacking the mutation with similar mtDNA copy numbers were used for the biochemical characterization.

Mitochondrial RNase P cleavage assay

The wild-type and mutant precursors of tRNA^A sp corresponding to mtDNA at positions 7478 (5′) to 7613 (3′), and tRNA^Ser(UCN) at mtDNA positions 7550 (5′) to 7419 (3′) were cloned into the pCRII-TOPO vector carrying SP6 and T7 promoters (Clontech). After HindIII digestion, the labeled RNA substrates (136 nt for tRNA^A sp and 132 nt for tRNA^Ser(UCN)) were transcribed with T7 RNA polymerase, in the presence of 10 μM ATP, CTP, GTP and UTP, pH 7.5, and 10 units of RNase inhibitor at 37°C. Transcripts were purified by denaturing polyacrylamide gel electrophoresis (PAGE) [8 M urea, 8% polyacrylamide/bisacrylamide (19:1)] and were dissolved in 1 mM EDTA. Mitochondrial RNase P was reconstituted from purified recombinant proteins MRPP1, MRPP2 and MRPP3 as described previously (15,26). The reaction mixture was incubated in 40 μl assay buffer containing 20 mM HEPES (pH 7.6), 20 mM KCl, 2 mM MgCl₂, 2 mM DTTP, 0.1 mg/ml bovine serum albumin, 80 μM 5′-adenosyl methionine, 1 U Ribolock RNase Inhibitor (Thermo Fisher Scientific), 300 ng pre-tRNAs, 800 nM MRPP1/2 and 100 nM MRPP3. The reaction mixes were pre-incubated at 30°C for 15 min, and the reaction was initiated by addition of MRPP3 and pre-tRNA substrates with subsequent incubation at 30°C. After 5, 10, 15, 20, 25 and 40 min, 5 μl of aliquots were withdrawn and stopped by addition of 5 μl loading buffer (85% formamide, 10 mM
Mitochondrial RNA analysis

Total RNAs were obtained by using TOTALY RNA™ kit (Ambion) from intact cells or mitochondria isolated from mutant and control cell lines (~2 × 10⁶ cells), as detailed elsewhere (39). For tRNA Northern blot analysis, 6 μg of total cellular RNA was electrophoresed through a 10% polyacrylamide/8 M urea gel in 1× TBE buffer after heating the samples at 65°C for 10 min, and then electroblotted onto a positively charged Nylon membrane (Roche) for the hybridization analysis with digoxigenin (DIG)-labeled oligodeoxynucleotide probes, respectively. A set of DIG-labeled probes of 22 mitochondrial tRNAs and 5S rRNA was described elsewhere (26,40,41). The hybridization and quantification of density in each band were performed as detailed previously (40–43).

For mRNA Northern blot analysis, 6 μg of total cellular RNA was fractionated by electrophoresis through a 2% agarose-formaldehyde gel, transferred onto a positively charged membrane (Roche) and hybridized with a set of DIG-labeled RNA probes: COX2, CYTB, ND1, ND3, ND6, COX1, 12S rRNA, 16S rRNA and β-actin as a control, respectively. Probes were synthesized as described previously (13,26,44). The hybridization and quantification of density in each band were performed as detailed previously (26,44).

Western blot analysis

Western blot analysis was performed as detailed previously (40,45,46). Twenty micrograms of total cell proteins obtained from various cell lines were denatured and loaded on sodium dodecyl sulfate polyacrylamide gels. The gels were electroblotted onto a polyvinylidene difluoride membrane for hybridization. The antibodies obtained from different companies were as follows: Abcam [TOM20 (ab56783), ND1 (ab74257), ND5 (ab92624), CO1 (ab695), CO2 (ab110258), ND6 (ab81212), Total OXPHOS Human WB Antibody Cocktail (ab110411) and CYTC (ab13575)], Cell Signaling Technology [Cleaved Caspase 3 (#9664), Cleaved Caspase 9 (#7237), Cleaved PARP (#5625), SOD1 (4266T), SOD2 (13141T) and Catalase (12980T)], Novus [ND4 (NBP2-47365)] and Proteintech [CYTB (55090-1-AP), ATP8 (26723-1-AP), CO3 (55082-1-AP), Afg3l2 (14631-1-AP), Clpp (15698-1-AP), Lonp1 (66043-1-AP) and GAPDH (10494-1-AP)]. Peroxidase AffiniPure goat anti-mouse IgG and goat anti-rabbit IgG (Jackson) were used as a secondary antibody and protein signals were detected using the ECL system (CW BIO). Quantification of density in each band was performed as detailed previously (40,45,46).

Measurements of oxygen consumption

The oxygen consumption rates (OCRs) in cybrid cell lines were measured with a Seahorse Bioscience XF-96 Extracel-
matrilineal relatives exhibited no other clinical abnormalities, including cardiac failure, muscular diseases, visual loss and neurological disorders. There was no evidence that any member of this family had any other known causes to account for hearing impairment. Further analysis showed that the m.7516delA mutation was present in homoplasmy in the all matrilineal relatives but not in other members of this family (Supplementary Table S2).

The aberrant 5′ end processing of tRNA{\text{Asp}} and tRNA{\text{Ser(UCN)}} precursors

To examine whether the m.7516delA mutation altered the 5′ end processing efficiencies of tRNA{\text{Asp}} from the H-strand transcripts and tRNA{\text{Ser(UCN)}} from the L-strand transcripts, we performed an in vitro processing experiment using RNase P that was reconstituted from purified recombinant proteins MRPP1, MRPP2 and MRPP3 as described previously (15,25,26). As illustrated in Figure 2A and B, the wild-type and mutant tRNA{\text{Asp}} and tRNA{\text{Ser(UCN)}} precursors corresponding to mtDNA at positions 7478–7613 and 7550–7419 were prepared by in vitro transcription, respectively. To analyze the in vitro processing kinetics, the wild-type and mutant tRNA{\text{Asp}} and tRNA{\text{Ser(UCN)}} precursors were incubated with RNase P at various time courses. The relative processing efficiencies were calculated by the ratios of cleaved pre-tRNAs at the plateau phase according to the fitted curve under exponential equation (one-phase association). As shown in Figure 2C–F, the processing efficiencies of the mutant tRNA{\text{Asp}} and tRNA{\text{Ser(UCN)}} transcripts were significantly reduced, as compared with those of wild-type counterparts. In particular, the processing efficiencies of mutant tRNA{\text{Asp}} and tRNA{\text{Ser(UCN)}} transcripts catalyzed by RNase P were ~67% and ~53% of those in their wild-type counterparts (Figure 2E and F), respectively. These results demonstrated that the m.7516delA mutation perturbed the 5′ end processing of tRNA{\text{Asp}} and tRNA{\text{Ser(UCN)}} precursors.

Reduced levels of tRNA{\text{Asp}} from H-strand transcripts and six tRNAs from L-strand transcripts

To test the hypothesis that the aberrant 5′ end processing of tRNA{\text{Asp}} and tRNA{\text{Ser(UCN)}} by the m.7516delA mutation affected other tRNA processing and subsequently reduced the levels of tRNAs, we subjected total cellular RNAs from mutant and control cell lines to Northern blots and hybridized them with DIG-labeled oligodeoxynucleotide probes for 14 tRNAs including tRNA{\text{Asp}}, tRNA{\text{Lys}}, tRNA{\text{Ser(UUR)}} and tRNA{\text{Ser(AGY)}} derived from the H-strand transcripts and 8 tRNAs including tRNA{\text{Ser(UCN)}} derived from the L-strand transcripts (7,13,26). As shown in Figure 3, the average levels of tRNA{\text{Asp}} and tRNA{\text{Ser(UCN)}} in three mutant cybrids were 53% and 44% (P < 0.01) of the mean values of three control cybrids, respectively. Strikingly, the average steady-state levels of five tRNAs, downstream of tRNA{\text{Ser(UCN)}} from the L-strand transcripts, were significantly decreased. Especially, the average levels of tRNA{\text{Thr}}, tRNA{\text{Cys}}, tRNA{\text{Lys}}, tRNA{\text{Ala}} and tRNA{\text{Glu}} in three mutant cybrids were 48%, 51%, 47%, 51% and 46% of those in three control cybrids, respectively. However, the levels of tRNA{\text{Pro}} and tRNA{\text{Gln}} from upstream of tRNA{\text{Ser(UCN)}} in the L-strand transcripts and other 13 tRNAs including tRNA{\text{Lys}}, tRNA{\text{Leu(UCN)}} and tRNA{\text{Ser(AGY)}} from the H-strand transcripts in the mutant cybrids were comparable with those in three control cybrids. These data indicated that the m.7516delA mutation led to the asymmetrical defects of tRNAs from H-strand and L-strand transcripts, respectively.

Aberrant processing of COX2 mRNA precursor

We then examined whether the m.7516delA mutation perturbed the processing of mRNA, 12S rRNA and 16S rRNA, and caused the accumulation of longer and un-cleaved precursors. RNA transfer hybridization experiments were performed with total cellular RNAs from various mutant and control cybrids, using a set of DIG-labeled RNA probes: ND6 from L-strand transcript, ND1, ND3, COX1, COX2, CYTB, 12S rRNA and 16S rRNA from H-strand transcript (13,26) and β-actin as a control. As shown in Figure 4A and B, two RNA species with ~0.83 and ~0.7 kb long were detected using COX2 probe in both mutant and control cell lines. As shown in Figure 4B, the analyses using both tRNA{\text{Asp}} and anti-tRNA{\text{Ser(UCN)}} probes only detected one RNA with ~0.83 kb long. The ~0.7 kb RNA was equal in size to 684-nt coding sequence of COX2 mRNA. Thus, the 0.83 kb RNA could conceivably be a precursor of COX2 mRNA, consisting of 72-nt noncoding sequence (7446–7517), 68-nt coding sequence of tRNA{\text{Asp}} (7518–7585) and 684-nt coding sequence of COX2. To verify the putative COX2 mRNA, three CDNA fragments [684 bp (COX2 coding sequence at positions 7586–8269), 755 bp (at positions 7515–8269) and 824 bp (at positions 7446–8269)] from the control cell line C17.1 and mutant cell line III-3.1 were analyzed by Sanger sequencing after cDNA synthesis and PCR amplification (Supplementary Figure S3). Indeed, all three fragments contained the identical 684 bp COX2 coding sequence, while 755 bp harboring 68-nt coding sequence of tRNA{\text{Asp}} and 3 bp noncoding sequence and 824 bp fragments encompassed the 68-nt coding sequence of tRNA{\text{Asp}} and coding sequence and 5′ untranslated sequences. This result confirmed that ~0.7 kb RNA was indeed COX2 mRNA. As shown in Figure 4A and D, the mutant cell lines displayed decreased levels of COX2 mRNA but accumulated precursors of COX2, as compared with those in the control cell lines. The average levels of COX2 mRNA and its precursors in three mutant cybrids, normalized with respect to those of β-actin mRNA, were 68.5% and 130.1% of those in the control cell lines, respectively (P < 0.01). However, the levels of ND1, ND3, COX1, CYTB, 12S rRNA and 16S rRNA from H-strand transcripts and ND6 from L-strand transcripts in mutant cybrids, normalized with respect to those of β-actin mRNA, were comparable with those in the control cell lines (Figure 4C and Supplementary Figure S4). These results demonstrated that the m.7516delA mutation perturbed the processing of COX2 mRNA precursors but did not affect the processing of other mRNAs and rRNAs from the H-strand and L-strand transcripts.
Figure 2. *In vitro* assay for the processing of tRNA^{Ser(UCN)} and tRNA^{Asp} precursors. (A, B) Mitochondrial tRNA^{Ser(UCN)} and tRNA^{Asp} precursors. Forty and 36 nucleotides (nt) of 5' end leaders, and 28 and 27 nt of the 3' end trailer of tRNA^{Ser(UCN)} and tRNA^{Asp} were shown, respectively. (C, D) *In vitro* processing assays. Processing assays with RNase P were carried out in parallel for wild-type and mutant substrates. Samples were withdrawn and stopped after 5, 10, 15, 20 or 40 min, respectively. Reaction products were resolved by denaturing PAGE and were visualized by staining with NA-Red (Beyotime). (E, F) Quantification of the efficiencies of tRNA^{Ser(UCN)} and tRNA^{Asp} precursors catalyzed by RNase P. The relative processing efficiencies were calculated by the ratios of cleaved pre-tRNAs at the plateau phase according to the fitted curve under exponential equation (one-phase association). The calculations were based on four independent determinations. The error bars indicate two standard errors of the mean.
Figure 3. Northern blot analysis of mitochondrial tRNAs. (A) Six micrograms of total cellular RNAs from the various cell lines were electrophoresed through a 10% denaturing polyacrylamide gel, electroblotted and hybridized with DIG-labeled oligonucleotide probes specific for tRNA\textsuperscript{Ser(UCN)}, tRNA\textsuperscript{Asn}, tRNA\textsuperscript{Pro}, tRNA\textsuperscript{Glu}, tRNA\textsuperscript{Gln}, tRNA\textsuperscript{Ala}, and tRNA\textsuperscript{Gly} from the L-strand transcripts, tRNA\textsuperscript{Asp}, tRNA\textsuperscript{Phe}, tRNA\textsuperscript{Val}, tRNA\textsuperscript{Leu(UUR)}, tRNA\textsuperscript{Ile}, tRNA\textsuperscript{Met}, tRNA\textsuperscript{Try}, tRNA\textsuperscript{Ala}, tRNA\textsuperscript{Arg}, tRNA\textsuperscript{His}, tRNA\textsuperscript{Ser(AGY)}, tRNA\textsuperscript{Leu(CUN)} and tRNA\textsuperscript{Thr} from the H-strand transcripts, and 5S rRNA, respectively. (B) Quantification of the tRNA levels. Average relative each tRNA content per cell was normalized to the average content per cell of 5S rRNA in the control and mutant cybrids, respectively. The values for the latter were expressed as percentages of the average values for the control cybrids. The calculations were based on three independent determinations in each cybrids. The error bars indicate two standard errors of the mean. P indicates the significance, according to the t-test, of the difference between mutant and control cybrids.
The impairment of mitochondrial translation

To examine whether the m.7516delA mutation impaired mitochondrial translation, a Western blot analysis was carried out to examine the levels of nine mtDNA-encoded polypeptides [ND1, ND4, ND5 and ND6 (subunits 1, 4, 5 and 6 of NADH dehydrogenase), CO1, CO2, CO3 (subunit I, II and III of cytochrome c oxidase), CYTB (apocytochrome b) and ATP8 (subunit 8 of H+^-ATPase)] in mutant and control cybrids with a nucleus-encoded mitochondrial protein TOM20 as a loading control. As shown in Figure 5A and B, the overall levels of nine mitochondrial translation products in the mutant cell lines were 71.6% (P < 0.001), relative to the mean value measured in the control cell lines. The average levels of ND1, ND4, ND5, ND6, CO1, CO2, CO3, ATP8 and CYTB in the mutant cells were 116.5%, 43.1%, 39.6%, 114.9%, 50.9%, 60.6%, 49.3%, 92.6% and 92.3% of those in the control cell lines after normalization to TOM20, respectively.

We then examined the levels of five subunits (CO2, NDUFB8 of NADH:ubiquinone oxidoreductase, SDHB of succinate ubiquinone oxidoreductase, UQCRC2 of ubiquinol cytochrome c reductase and ATP5A of H+^-ATPase) of the phosphorylation system (OXPHOS) in the control and mutant cybrids. As shown in Supplementary Figure S5, the average levels of CO2 in the mutant cells were 65.6% (P = 0.018) of control cell lines, while the levels of NDUFB8, SDHB, UQCRC2 and ATP5A in the mutant cell lines were comparable with those in control cell lines.

The m.7516delA mutation induced proteostasis stress

To test whether the m.7516delA mutation-induced deficiency affected the mitochondrial proteostasis, we measured the levels of Lonp1 involved in the maintenance of mitochondrial proteostasis and gene expression (54), Clpp involved in mitochondrial ribosome assembly (55) and ATP family gene 3-like2 (Afg3l2) proteases involved in the turnover of misfolded protein markers for proteostasis stress (56), in the mutant and control cybrids. As shown in Figure 5C and D, the levels of Lonp1, Afg3l2 and Clpp in the mutant cell lines were 136.2% (P < 0.01), 160.8% (P < 0.01) and 153.6% (P < 0.01) of those in the control cell lines after normalization to GAPDH, respectively. These data indicated that m.7516delA mutation induced the proteostasis stress.

Deficient activities of respiratory chain complexes

To evaluate whether the impairment of mitochondrial translation caused the deficient oxidative phosphorylation, we measured the activities of respiratory complexes by the use of isolated mitochondria from mutant and control cell lines. The activity of complex I (NADH ubiquinone oxidoreductase) was determined through the oxidation of
Figure 5. Analysis of mitochondrial translation and proteostasis stress. (A) Analysis of mtDNA-encoded proteins. Five micrograms of total mitochondrial proteins from various cybrids were electrophoresed through a denaturing polyacrylamide gel, electroblotted and hybridized with antibodies specific for ND1, ND4, ND5, ND6, CO1, CO2, CO3, CYTB and ATP8, with TOM20 as a loading control. (B) Quantification of nine polypeptides. The average relative values of ND1, ND4, ND5, ND6, CO1, CO2, CO3, CYTB and ATP8 in mutant and control cell lines were normalized to the average values of TOM20 in various cell lines. The values for the latter are expressed as percentages of the average values for the control cell lines. The calculations were based on three independent determinations. For multiple comparisons, two-way ANOVA was performed. (C) Western blotting analysis of LonP1, Afg3l2 and Clpp proteins. Twenty micrograms of total cellular proteins from various cybrids were electrophoresed through a denaturing polyacrylamide gel, electroblotted and hybridized with antibodies for LonP1, Afg3l2 and Clpp as well as GAPDH as a loading control. (D) Quantification of levels of LonP1, Afg3l2 and Clpp. The calculations were based on three independent experiments. Graph details and symbols are explained in the legend to Figure 3.

NADH with ubiquinone as the electron acceptor (57,58). The activity of complex II (succinate ubiquinone oxidoreductase) was examined through the artificial electron acceptor DCPIP. The activity of complex III (ubiquinone cytochrome c oxidoreductase) was measured through the reduction of cytochrome c by using D-ubiquinol-2 as the electron donor. The activity of complex IV (cytochrome c oxidase) was monitored through the oxidation of cytochrome c. Complex I–IV activities were normalized by citrate synthase activity. As shown in Figure 6A, the average activities of complexes I and IV in three mutant cybrids were 69.7% ($P < 0.001$) and 66.3% ($P < 0.001$) of the mean values measured in three control cybrids, respectively. However, the average activities of complexes II and III in three mutant cybrids were 99.1% ($P = 0.801$) and 95.7% ($P = 0.263$) of the mean values measured in three control cybrids, respectively.

Furthermore, we measured the OCRs of various mutant and control cybrid cell lines using a Seahorse Bioscience XF-96 Extracellular Flux Analyzer (47). As shown in Figure 6B and C, the average basal OCRs in three mutant cy-
Figure 6. Respiration and enzymatic activities assays. (A) Enzymatic activities of respiratory chain complexes. The activities of respiratory complexes were investigated by an enzymatic assay on complexes I, II, III and IV in mitochondria isolated from various cell lines. The calculations were based on three independent determinations. (B) An analysis of O₂ consumption rate (OCR) in the various cell lines using different inhibitors. The OCRs were first measured on 1 × 10⁴ cells of each cell line under basal condition and then sequentially added oligomycin (1.5 μM), carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone (FCCP) (0.5 μM), rotenone (1 μM) and antimycin A (1 μM) at indicated times to determine different parameters of mitochondrial functions. (C) Graphs presented the ATP-linked OCR, proton leak OCR, maximal OCR, reserve capacity OCR and non-mitochondrial OCR in mutant and control cell lines. Non-mitochondrial OCR was determined as the OCR after rotenone/antimycin A treatment. Basal OCR was determined as OCR before oligomycin minus OCR after oligomycin. Proton leak OCR was determined as basal OCR minus ATP-linked OCR. Maximal OCR was determined as the OCR after FCCP minus non-mitochondrial OCR. Reserve capacity OCR was defined as the difference between maximal OCR after FCCP minus basal OCR. The average values of three determinations for each cell line are shown. Graph details and symbols are explained in the legend to Figure 3.
bridges were 67.7\%(P < 0.01) of the mean values measured in three control cybrids. To further investigate which of the enzyme complexes of the respiratory chain was affected in the mutant cybrids, OCR was measured after the sequential addition of oligomycin (to inhibit the ATP synthase), FCCP (to uncouple the mitochondrial inner membrane and allow for maximum electron flux through the ETC), antimycin A (to inhibit complex III) and rotenone (to inhibit complex I). As shown in Figure 6C, the ATP-linked OCR, proton leak OCR, maximal OCR, reserve capacity OCR and non-mitochondrial OCR in mutant cybrids were 69.9\%(P < 0.001), 59.2\%(P < 0.001), 58.3\%(P < 0.001), 45.7\%(P < 0.001) and 86.9\%(P = 0.179), relative to the mean values measured in the control cybrids, respectively.

Decreases in mitochondrial membrane potential
The mitochondrial membrane potential (ΔΨm) generated by proton pumps (complexes I, III and IV) is an essential component in the process of energy storage during oxidative phosphorylation (40,50). The mitochondrial membrane potentials (ΔΨm) of mutant and control cybrids were examined through the fluorescence probe JC-10 assay system. The ratios of fluorescence intensities Ex/Em = 490/590 and 490/530 nm (FL590/FL530) were recorded to delineate the ΔΨm of each sample. The relative ratios of FL590/FL530 geometric mean between mutant and control cybrids were calculated to represent the level of ΔΨm, as described elsewhere (46,50). As illustrated in Figure 7, ΔΨm of three mutant cybrids ranged from 53.2\% to 59.8\%, with an average of 57.1\%(P < 0.001) of the mean value measured in three control cybrids. In contrast, the levels of ΔΨm in three mutant cell lines in the presence of FCCP were comparable to those of three control cell lines.

The increase of mitochondrial ROS production
Mitochondrial ROS are gradually recognized as important signaling mediators in a wide range of cellular processes (59). To test whether the m.7516delA mutation elevated the production of mitochondrial ROS, the levels of mitochondrial ROS generation in the mutant and control cybrids were determined using the MitoSOX assay via flow cytometry (25,51,52). Geometric mean intensity was recorded to represent the level of ΔΨm between mutant and control cybrids were 69.9\%(P < 0.001), 59.2\%(P < 0.001), 58.3\%(P < 0.001), 45.7\%(P < 0.001) and 86.9\%(P = 0.179), relative to the mean values measured in the control cybrids, respectively.

To assess whether the m.7516delA mutation affects the apoptotic processes, we examined the apoptotic state of mutant and control cybrids by Annexin V-FITC/PI assay using the flow cytometry (53) and Western blot analyses. As shown in Figure 9A and B, the levels of early and late apoptosis in the mutant cybrids carrying the m.7516delA mutation ranged from 204.8\% to 226.7\%, with an average of 214.9\%(P < 0.001) of the mean values measured in the control cybrids. Cytochrome c released from mitochondria recruits and activates apoptosis-activated proteins such as procaspase 9 and then stimulates apoptosis (61). We then performed western blot analysis to further evaluate the effect of m.7516delA mutation on apoptosis by measuring the levels of cytochrome c and three apoptosis-activated proteins [cleaved caspases 9 and 3 and cleaved poly(ADP-ribose) polymerase (Parp)] in mutant and control cybrids (61). As shown in Figure 9C, the marked increasing levels of cytochrome c and three apoptosis-activated proteins were observed in the mutant cell lines. As shown in Figure 9D, the average levels of cytochrome c, Caspase 9, Caspase 3 and Parp in three mutant cell lines were 146.3\%, 119.2\%, 230.1\% and 214.2\% of the mean values measured in three control cell lines, respectively (P < 0.01).

DISCUSSION
In this study, we demonstrated the profound impact of deafness-associated m.7516delA mutation on mitochondrial RNA processing contributing to the pathological process of deafness. This mutation was only present in the maternal relatives of the Chinese family with maternal inheritance of deafness. In fact, the m.7516delA mutation located at 3 bp (7515AAA/TTT7517) spacers between tRNAAsp and tRNA Ser(UCN) (4,27). The 3 bp (AAA/TTT) spacers are the 5' end processing sites of tRNAAsp from the H-strand transcripts and tRNA Ser(UCN) from the L-strand transcripts, catalyzed by RNase P (6,7,10). Therefore, the primary defects arising from the deletion of adenine at position 7516 were the aberrant 5' end processing of tRNAAsp from H-strand transcripts and the tRNA Ser(UCN) from the L-strand transcripts. These tRNA processing defects were evidenced by reduced efficiencies of the 5' end processing of tRNAAsp and tRNA Ser(UCN) precursors carrying the m.7516delA mutation, catalyzed by RNase P, in vitro processing experiment and supported by decreased levels of tRNAAsp and tRNA Ser(UCN) observed in the cells bearing the m.7516delA mutation. However, there were remarkable differences in RNA processing defects arising from the m.7516delA mutation between the L-strand and H-strand polycistronic transcripts. On the H-strand transcript, the aberrant tRNAAsp 5' end processing caused by the m.7516delA mutation specifically altered the processing of downstream COX2 precursors, evidenced by lower levels of COX2 mRNA and the accumulation of longer and uncleaved precursors [72 nt (7446–7517) + tRNAAsp + COX2] in the mutant cybrids, as compared with those in control cybrids. These reflected the complexity of the RNA processing of mitochondrial polycistronic transcripts, in addition to the tRNA punctuation model (7). In contrast, the m.7516delA mutation did not affect the processing of other 13 tRNAs includ-
Figure 7. Mitochondrial membrane potential analysis. The mitochondrial membrane potential (ΔΨm) was measured in mutant and control cell lines using a fluorescence probe JC-10 assay system. The ratios of fluorescence intensities Ex/Em = 490/590 and 490/530 nm (FL590/FL530) were recorded to delineate the ΔΨm level of each sample. The relative ratios of FL590/FL530 geometric mean between mutant and control cell lines were calculated to reflect the level of ΔΨm. (A) Represented flow cytometry images of mutant and control cell lines without and with 10 μM FCCP. Relative ratio of JC-10 fluorescence intensities at Ex/Em = 490/525 and 490/590 nm in the absence (B) and presence (C) of 10 μM FCCP in three control cell lines and three mutant cell lines. The average of three determinations for each cell line is shown. Graph details and symbols are explained in the legend to Figure 3.

| Controls | Mutants |
|----------|---------|
| C17.1    | III-3.1 |
| C17.2    | III-3.2 |
| C17.3    | III-3.3 |

Table showing the distribution of mitochondrial membrane potential (ΔΨm) in mutant and control cell lines with and without 10 μM FCCP.

- FCCP
- + FCCP

Graph (B) showing the membrane potential (ΔΨm) of cell lines without FCCP, where P < 0.001 indicates a significant difference.

Graph (C) showing the membrane potential (ΔΨm) of cell lines with FCCP, where P = 0.606 indicates no significant difference.

11124 Nucleic Acids Research, 2020, Vol. 48, No. 19
of ∼28.4%) in nine mtDNA-encoded polypeptides, comparable effects seen in cells bearing the m.4263A>G, m.4401A>G or m.5655A>G mutation (24–26). Notably, mutant cybrids carrying the m.7516delA mutation exhibited marked reductions (44–65%) in the levels of five polypeptides (ND4, ND5, CO1, CO2 and CO3) harboring higher numbers of these codons. Strikingly, the reduction of CO2 resulted from both shortage of seven tRNAs and lower levels of COX2 mRNA, caused by the m.7516delA mutation. However, the levels of CYTB with higher numbers or proportions of these codons in mutant cybrids were comparable with those in control cybrids, while mutant cybrids displayed minor reductions (4%) in the levels of ATP8 carrying relative lower numbers of codons and even mild increases (∼5%) in the levels of ND1 and ND6 bearing extremely lower numbers of codons. Thus, no significant correlation of the reduced levels of these polypeptides in mutant cybrids with the numbers or proportions of overall aspartic acid, serine (UCN), alanine, tyrosine, asparagine, cysteine and glutamin codons (Supplementary Table S3), was in contrast with to what was previously shown in cells carrying the tRNA^{Lys} 8344A>G and tRNA^{Ser(UCN)} 7445A>G mutations (13,62). Alternatively, these translational defects may be due to the m.7516delA-induced mitochondrial stalling during the translation process, as in the case of tRNA^{Leu(UUR)} 3243A>G mutation (63).

Furthermore, the levels of four subunits of OXPHOS complexes (NDUFB8, SDHB, UQCRC2 and ATP5A) encoded by nuclear genes were not changed in the mutant cybrids bearing the m.7516delA mutation, indicating no effect of the m.7516delA mutation on the stability of OXPHOS complexes. However, the aberrant synthesis of mtDNA-encoded proteins produced the proteostasis stress, such as elevating the protein degradation in mitochondria, was evidenced by the increased levels of Lonp1, Afg3l2 and Clpp in the mutant cell lines (54–56,64).

The alterations in mitochondrial translation and induced proteostasis stress led to the deficient oxidative phosphorylation, increased ROS production and subsequent failure of cellular energetic processes (9,65–67). In particular, the impaired synthesis of ND4, ND5, CO1, CO2 and CO3 resulted in the decreased activities of complexes I and IV. Furthermore, the impairment of mitochondrial translation yielded the reduced rates in the basic OCR, ATP-linked OCR, proton leak OCR, reserve capacity OCR and maximal OCR in the mutant cell lines. The resultant respiratory deficiencies diminished mitochondrial ATP production and membrane potential and increased the ROS production. Alterations in OXPHOS and mitochondrial membrane potential as well as elevation of mitochondrial ROS production induced mitochondria-dependent apoptotic death (31,42,68,69). In this study, cybrids harboring the m.7516delA mutation displayed heightened vulnerability to apoptotic induction. These were evidenced by the elevated release of cytochrome c into cytosol and increased levels of caspases 3, 7 and 9 and PARP observed in cell...
Figure 9. Analysis of apoptosis. (A) Annexin V/PI apoptosis assay by flow cytometry. Cells were harvested and stained with Annexin V and 1 μl of PI. Flow cytometric plots show cells in the live, early apoptosis and late apoptosis stages. Apoptosis rate increased in mutant cells compared with control cells. (B) Relative Annexin V-positive cells from various cell lines. Three independent determinations were done in each cell line. (C) Western blot analysis of cytochrome C and three apoptosis-activated proteins. Twenty micrograms of total proteins from various cell lines were electrophoresed, electroblotted and hybridized with cleaved Caspase 9, cleaved Parp and cleaved Caspase 3 antibodies and with GAPDH as a loading control. (D) Quantification of four proteins associated with apoptosis. Three independent determinations were done in each cell line. Graph details and symbols are explained in the legend to Figure 3.

lines carrying the m.7516delA mutation, as compared to control cybrids. These data suggested that mitochondrial dysfunction caused by the m.7516delA mutation promoted the apoptosis on the hair cells and neurons in the cochlea, because cochlear functions depended on a very high rate of ATP production (70,71). However, the incomplete penetrance of deafness and relatively mild biochemical defects indicated that the m.7516delA mutation might not be sufficient to produce the deafness phenotype. The nuclear modifier genes may contribute to the development of hearing-specific phenotype in these subjects carrying the mtDNA mutation(s) (72). Alternatively, the tissue-specific effects may arise from differential expression of tRNA genes (73,74) or variable activations of the integrated stress response pathway, metabolic changes and the ability of certain tissues to respond to impaired mitochondrial translation (75).

In summary, we demonstrated the profound impact of deafness-associated m.7516delA mutation on mitochondrial RNA processing contributing to the pathological process of deafness. The primary defects in the m.7516delA mutation were the aberrant 5′ end processing of tRNAAsp and tRNASer(UCN) precursors. The m.7516delA mutation caused the low levels of tRNAAsp and COX2 mRNA and the accumulation of longer and uncleaved precursors of COX2 from the H-strand transcript, and the significant decreases in the levels of tRNASer(UCN) and downstream five tRNAs from the L-strand transcript. These data demonstrated the asymmetrical effect of m.7516delA mutation on the expression of RNA from H-strand and L-strand polycistronic transcripts. These RNA metabolic defects resulted in the impairment of mitochondrial translation, proteostasis stress, respiratory deficiency, diminished membrane potential, increased production of reactive oxygen species and promoted apoptosis. Our findings provide new insights into the pathophysiology of maternal transmission of deafness arising from mitochondrial tRNA processing defects.
SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS

We are grateful to patients and their family members for their participation.

FUNDING

Ministry of Science and Technology of Zhejiang Province [2018C03026]; National Key Research and Development Program of China [2018YFC1004802]; National Basic Research Priorities Program of China [2014CB541704 to M.-X.G.]; National Natural Science Foundation of China [82030028 to M.-X.G., 81670932 to H.W.]; The Key Projects of Shandong Provincial Programs for Research and Development [2017CXSJ1213 to H.W.].

Conflict of interest statement. None declared.

REFERENCE

1. Suzuki,T., Nagao,A. and Suzuki,T. (2011) Human mitochondrial tRNAs: biogenesis, function, structural aspects, and diseases. Ann. Rev. Genet., 45, 299–329.
2. Hällberg,B.M. and Larsson,N.G. (2014) Making proteins in the powerhouse. Cell Metab., 20, 226–240.
3. D’Souza,A.R. and Miniczk,M. (2018) Mitochondrial transcription and translation: overview. Essays Biochem., 62, 309–320.
4. Anderson,S., Bankier,A.T., Barrell,B.G., de Bruijn,M.H., Coulson,A.R., Drouin,J., Eperon,I.C., Nierlich,D.P., Roe,B.A., Sanger,F. et al. (1981) Sequence and organization of the human mitochondrial genome. Nature, 290, 457–465.
5. Attardi,G. and Schatz,G. (1988) Biogenesis of mitochondria. Ann. Rev. Cell Biol., 4, 289–333.
6. Montoya,J., Ganes,G.L. and Attardi,G. (1983) The pattern of transcription of the human mitochondrial rRNA genes reveals two overlapping transcription units. Cell, 34, 151–159.
7. Ojala,D., Montoya,J. and Attardi,G. (1981) RNA punctuation model of RNA processing in human mitochondria. Nature, 290, 470–474.
8. Scarpulla,R.C. (2008) Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol. Rev., 88, 611–638.
9. Wallace,D.C. (2005) A mitochondrial paradigm of metabolic and medicine. Ann. Rev. Genet., 39, 359–407.
10. Mercer,T.R., Neph,S., Dinger,M.E., Crawford,J., Smith,M.A., Shearwood,A.M., Haugen,E., Bracken,C.P., Rackham,O., Stamatoyannopoulos,J.A. et al. (2011) The human mitochondrial transcriptome. Cell, 146, 645–658.
11. Fisher,R.P., Topper,J.N. and Clayton,D.A. (1987) Promoter selection in human mitochondria involves binding of a transcription factor to orientation-independent upstream regulatory elements. Cell, 50, 247–258.
12. Sanchez,M.I., Mercer,T.R., Davies,S.M., Shearwood,A.M., Nygaard,K.K., Richman,T.R., Mattick,J.S., Rackham,O. and Filipovska,A. (2011) RNA processing in human mitochondria. Cell Cycle, 10, 2904–2916.
13. Van Haute,L., Pearce,S.F., Powell,C.A., D’Souza,A.R., Nicholls,T.J. and Miniczuk,M. (2015) Mitochondrial transcription and maturation in its disorders. J. Inherit. Metab. Dis., 38, 655–680.
14. Yan,H., Zareen,N. and Levinger,L. (2006) Naturally occurring mutations in human mitochondrial pre-tRNAHis(CUA) can affect the transfer ribonuclease Z cleavage site, processing kinetics, and substrate secondary structure. J. Biol. Chem., 281, 3926–3935.
15. Levinger,L., Giege,R. and Florentz,C. (2003) Pathology-related substitutions in human mitochondrial tRNAle induce precursor 3′ end processing efficiency in vitro. Nucleic Acids Res., 31, 1904–1192.
16. Reinhart,L., Sidhara,S. and Hallberg,B.M. (2017) The MRPP1/MRPP2 complex is a tRNA-maturation platform in human mitochondria. Nucleic Acids Res., 45, 12469–12480.
17. Temper,R.J., Wydor,M., Lightowlers,R.N. and Chrzanowska-Lightowlers,Z.M. (2010) Human mitochondrial mRNAs—like members of all families, similar but different. Biochim. Biophys. Acta, 1797, 1081–1085.
18. Van Haute,L., Pearce,S.F., Powell,C.A., D’Souza,A.R., Nicholls,T.J. and Miniczuk,M. (2015) Mitochondrial transcription and maturation in its disorders. J. Inherit. Metab. Dis., 38, 655–680.
19. Yan,H., Zareen,N. and Levinger,L. (2006) Naturally occurring mutations in human mitochondrial pre-tRNAHis(CUA) can affect the transfer ribonuclease Z cleavage site, processing kinetics, and substrate secondary structure. J. Biol. Chem., 281, 3926–3935.
20. Levinger,L. and Serjanov,D. (2012) Pathogenesis-related mutations in the T-loops of human mitochondrial tRNAs affect 3′ end processing and tRNA structure. RNA Biol., 9, 283–291.
21. Xu,L., Wang,M., Li,H., Wang,H., Jiang,F., Hou,L., Geng,J., Lin,Z., Peng,Y., Zhou,H. et al. (2016) Mitochondrial tRNA mutations in 2070 Chinese Han subjects with hypertension. Mitochondrion, 30, 208–221.
22. Li,R., Liu,Y., Li,Z., Yang,L., Wang,S. and Guan,M.X. (2009) Failures in mitochondrial tRNAmet and tRNAglm metabolism caused by the novel 4401A>G mutation are involved in essential hypertension in a Han Chinese Family. Hypertension, 54, 329–337.
23. Wang,S., Li,R., Fettermann,A., Li,Z., Qian,Y., Liu,Y., Wang,X., Zhou,A., Mo,J.Q., Yang,L. et al. (2011) Maternally inherited essential hypertension is associated with the novel 4263A>G mutation in the mitochondrial tRNAle gene in a large Han Chinese family. Circ. Res., 108, 862–870.
24. Jiang,P., Wang,M., Xue,L., Xiao,Y., Yu,J., Wang,H., Yao,J., Liu,H., Peng,Y., Liu,H. et al. (2016) A hypertension-associated tRNAhis mutation alters tRNA metabolism and mitochondrial function. Mol. Cell. Biol., 36, 1920–1930.
25. Zhao,X., Cui,L., Xiao,Y., Mao,Q., Aishanjiang,M., Kong,W., Liu,Y., Chen,H., Hong,F., Jia,Z., Wang,M., Jiang,P. and Guan,M.X. (2019) Hypertension-associated mitochondrial DNA 4401A>G mutation caused the aberrant processing of tRNAmet, all 8 tRNAs and ND6 mRNA in the light-strand transcript. Nucleic Acids Res., 47, 10340–10356.
26. Zheng,J., Bai,X., Xiao,Y., Ji,Y., Meng,F., Aishanjiang,M., Gao,Y., Wang,H., Fu,Y. and Guan,M.X. (2020) Mitochondrial tRNA mutations in 887 Chinese subjects with hearing loss. Mitochondrion, 52, 163–172.
27. Florentz,C., Sohn,B., Tryoen-Toth,P., Putz,J. and Sissler,M. (2003) Human mitochondrial tRNAs in health and disease. Cell. Mol. Life Sci., 60, 1356–1375.
28. King,M.P. and Attardi,G. (1989) Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science, 246, 500–503.
29. Gong,S., Peng,Y., Jiang,P., Wang,M., Fan,M., Wang,X., Zhou,H., Li,H., Yan,Q. and Hu,J. (2014) A deafness-associated tRNAhis mutation alters the mitochondrial function. ROS production and membrane potential. Nucleic Acids Res., 42, 8039–8048.
30. Zhang,J., Bai,Y., Xu,M., Liu,Y., Yu,X., Zhou,H. and Guan,M.X. (2018) Leber’s hereditary optic neuropathy (LHON)-associated ND5 12338T>C mutation altered the assembly and function of complex I, apoptosis and mitophagy. Hum. Mol. Genet., 27, 1999–2011.
31. Guan,M.X., Fischel-Ghodsian,N. and Attardi,G. (2001) Nuclear background determines biochemical phenotype in the deafness-associated mitochondrial 12S rRNA mutation. Hum. Mol. Genet., 10, 573–580.
32. Zhao,H., Li,R., Wang,Q., Yan,Q., Deng,J.H., Han,D., Bai,Y., Young,W.Y. and Guan,M.X. (2004) Maternally inherited aminoglycoside-induced and nonsyndromic deafness is associated with the novel C1494T mutation in the mitochondrial 12S rRNA gene in a large Chinese family. Am. J. Hum. Genet., 74, 139–152.
33. Yan,X., Wang,X., Wang,Z., Sun,S., Chen,G., He,Y., Mo,J.Q., Li,R., Jiang,P., Lin,Q. et al. (2011) Maternally transmitted late-onset non-syndromic deafness is associated with the novel heteroplasmic
T12201C mutation in the mitochondrial tRNA\(^{\text{His}}\) gene. J. Med. Genet., 48, 682–690.

35. Andrews, R.M., Kubacka, I., Chinnery, P.F., Lightowers, R.N., Turnbull, D.M. and Howell, N. (1999) Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat. Genet., 23, 147.

36. Rieder, M.J., Taylor, S.L., Tobe, V.O. and Nickerson, D.A. (1998) Automating the identification of DNA variations using quality-based fluorescence re-sequencing: analysis of the human mitochondrial genome. Nucleic Acids Res., 26, 967–973.

37. Miller, G. and Lipman, M. (1973) Release of infectious Epstein–Barr virus by transformed marrowset leukocytes. Proc. Natl Acad. Sci. U.S.A., 70, 190–194.

38. Zhang, J., Liu, X., Liang, X., Lu, Y., Zhu, L., Fu, R., Ji, Y., Fan, W., Chen, J., Lin, B. et al. (2017) A novel ADOA-associated OPA1 mutation alters the mitochondrial function, membrane potential, ROS production and apoptosis. Sci. Rep., 7, 5704.

39. King, M.P. and Attardi, G. (1993) Post-transcriptional regulation of the steady-state levels of mitochondrial rRNAs in HeLa cells. J. Biol. Chem., 268, 10228–10237.

40. Zhou, M., Xue, L., Chen, Y., Li, H., He, Q., Wang, B., Meng, F., Wang, M. and Guan, M. (2018) A hypertension-associated mitochondrial DNA mutation introduces an m\(^{\text{G37}}\) modification into tRNA\(^{\text{Met}}\), altering its structure and function. J. Biol. Chem., 293, 1425–1438.

41. Jiang, P., Jin, X., Peng, Y., Wang, M., Liu, H., Liu, X., Zhang, Z., Ji, Y., Zhang, J., Liang, M. et al. (2016) The exome sequencing identified the mutation in YARS2 encoding the mitochondrial tyrosyl-tRNA synthetase as a nuclear modifier for the phenotypic manifestation of Leber’s hereditary optic neuropathy-associated mitochondrial DNA mutation. Hum. Mol. Genet., 25, 584–596.

42. Jia, Z., Zhang, X., Li, Q., Li, Y., Fu, C., Cang, X., Wang, M. and Guan, M. (2019) A coronary artery disease-associated tRNA\(^{\text{Thr}}\) mutation altered mitochondrial function, apoptosis and angiogenesis. Nucleic Acids Res., 47, 2056–2074.

43. Wang, M., Peng, Y., Zheng, J., Zheng, B., Jin, X., Liu, H., Wang, Y., Tang, X., Huang, T., Jiang, P. et al. (2016) A deafness-associated tRNA\(^{\text{Glu}}\) mutation alters the m\(^{\text{G37}}\) modification, aminoacylation and stability of tRNA\(^{\text{Glu}}\) and mitochondrial function. Nucleic Acids Res., 44, 10974–10985.

44. Li, X., Fischel-Ghodsian, N., Schwartz, F., Yan, Q., Friedman, R.A. and Guan, M. (2004) Biochemical characterization of the mitochondrial tRNA\(^{\text{Leu(UUR)}}\) (UUA, UUG) T7511C mutation associated with nonsyndromic deafness. Nucleic Acids Res., 32, 867–877.

45. Gong, S., Wang, X., Meng, F., Cui, L., Yi, Q., Zhao, Q., Cang, X., Cai, Z., Mo, J.Q., Liang, Y. et al. (2020) Overexpression of mitochondrial histidyl-tRNA synthetase restores mitochondrial dysfunction caused by a deafness-associated tRNA\(^{\text{Glu}}\) mutation. J. Biol. Chem., 295, 940–954.

46. Meng, F., He, Z., Tang, X., Zheng, J., Jin, X., Zhu, Y., Ren, X., Zhou, M., Wang, M., Gong, S. et al. (2018) Contribution of the tRNA\(^{\text{Leu(UUR)}}\) 4317A\(>\)G mutation to the phenotypic manifestation of the deafness-associated mitochondrial 12S rRNA 1555A\(>\)G mutation. J. Biol. Chem., 293, 3321–3334.

47. Dranka, B.P., Benavides, G.A., Diers, A.R., Giordano, S., Zelickson, B.R., Diers, A.R., Giordano, S., Zelickson, B.R., Reily, C., Zou, L., Chatham, J.C., Hill, B.G., Zhang, J. et al. (2011) Assessing bioenergetic function in response to oxidative stress by metabolic profiling. Free Radic. Biol. Med., 51, 1621–1635.

48. Li, Y., D’Aurelio, M., Deng, J.H., Park, J.S., Manfredi, G., Hu, P., Lu, J. and Bai, Y. (2007) An assembled complex IV maintains the stability and activity of complex I in mammalian mitochondria. J. Biol. Chem., 282, 17577–17582.

49. Thorburn, D.R., Chow, C.W. and Kirby, D.M. (2004) Respiratory chain enzyme analysis in muscle and liver. Mitochondrion, 4, 363–375.

50. Sena, L.A. and Chandel, N.S. (2012) Physiological roles of mitochondrial reactive oxygen species. Mol. Cell, 48, 158–167.

51. Schieber, M. and Chandel, N.S. (2014) ROS function in redox signaling and oxidative stress. Curr. Biol., 24, R453–R462.

52. Taylor, R.C., Cullen, S.P. and Martin, S.J. (2008) Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol., 9, 231–241.

53. Enríquez, J.A., Chomyn, A. and Attardi, G. (1995) Mitochondrial DNA mutation in MERRF syndrome causes defective aminoacylation of tRNA\(^{\text{Leu(UUR)}}\) and premature translation termination. Nat. Genet., 10, 47–55.

54. Chomyn, A., Enríquez, J.A., Micol, V., Fernandez-Silva, P. and Attardi, G. (2000) The mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episode syndrome-associated human mitochondrial tRNA\(^{\text{Leu(UUR)}}\)A\(>\)G mutation causes aminoacylation deficiency and concomitant reduced association of tRNA with ribosomes. J. Biol. Chem., 275, 19198–19209.

55. Hui, L., Cui, L., et al. (2017) A novel ADOA-associated OPA1 mutation. Nucleic Acids Res., 45, 3541–3555.

56. Münch, C. and Harper, J.W. (2016) Mitochondrial unfolded protein response controls matrix pre-RNA processing and translation. Nature, 534, 710–713.

57. Smeitink, J. van den Heuvel, L. and DiMauro, S. (2001) The genetics and pathology of oxidative phosphorylation. Nat. Rev. Genet., 2, 342–352.

58. Meng, F., Cang, X., Peng, Y., Li, R., Zhang, Z., Li, F., He, X., Ai, C., Wang, M. and Guan, M.X. (2019) Deletion of Gtpbp3 in zebrafish revealed the hypertrophic cardiomyopathy manifested by aberrant mitochondrial tRNA metabolism. Nucleic Acids Res., 47, 5341–5355.

59. Kawamata, H. and Manfredi, G. (2017) Proteinopathies and OXPHOS dysfunction in neurodegenerative diseases. J. Cell Biol., 216, 317–329.
73. Torres, A.G., Reina, O., Stephan-Otto Attolini, C. and Ribas de Pouplana, L. (2019) Differential expression of human tRNA genes drives the abundance of tRNA-derived fragments. Proc. Natl Acad. Sci. U.S.A., 116, 8451–8456.

74. Dittmar, K.A., Goodenbour, J.M. and Pan, T. (2006) Tissue-specific differences in human transfer RNA expression. PLoS Genet., 2, e221.

75. Agnew, T., Goldsworthy, M., Aguilar, C., Morgan, A., Simon, M., Hilton, H., Esapa, C., Wu, Y., Cater, H., Bentley, L. et al. (2018) A Wars2 mutant mouse model displays OXPHOS deficiencies and activation of tissue-specific stress response pathways. Cell Rep., 25, 3315–3328.